Brain noradrenergic receptors in major depression and schizophrenia

Violetta Klimek, Grazyna Rajkowska, Stephen N. Luker, Ginny Dilley, Herbert Y. Meltzer, James C. Overholser, Craig A. Stockmeier, Gregory A. Ordway*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


The binding of [125I]p-iodoclonidine to alpha-2, and/or [125I]iodopindolol to beta-1 and beta-2 adrenoceptors was measured in right prefrontal cortex (Brodmann's area 10) and right hippocampus from subjects with DSM-III-R diagnoses of major depression (n = 15) or schizophrenia (n = 8) as well as from control subjects (n = 20). No significant differences between study groups were observed in binding to alpha-2 adrenoceptors in any of the six layers of prefrontal cortex or in any of the hippocampal fields. Likewise, there were no significant differences in beta-1 or beta-2 adrenoceptor binding in any of the hippocampal fields between control and major depressive subjects. In contrast, binding to beta-1 adrenoceptors, but not beta-2 adrenoceptors, was significantly lower (-13 to -27%) in most hippocampal fields of schizophrenic subjects as compared to control subjects or to major depressives. Alterations in beta-1 adrenoceptor binding in the hippocampus of schizophrenics provide further evidence for a role of central noradrenergic neurons in the neurochemical pathology of schizophrenia. Copyright (C) 1999 American College of Neuropsychopharmacology.

Original languageEnglish (US)
Pages (from-to)69-81
Number of pages13
Issue number1
StatePublished - Jul 1999


  • Depression
  • Hippocampus
  • Noradrenergic receptors
  • Postmortem
  • Prefrontal cortex
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health


Dive into the research topics of 'Brain noradrenergic receptors in major depression and schizophrenia'. Together they form a unique fingerprint.

Cite this